Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Unveiling the endothelialization process of the WATCHMAN FLX Pro: beyond the resolution of conventional imaging.

European heart journal. Cardiovascular Imaging·2026

Same authorSame journal

Donor selection in living-donor lung transplantation for familial pulmonary fibrosis: A narrative review and single-center practical approach.

Respiratory investigation·2026

Same author

Safe and simple pulsed field ablation application using integrated 3D system for AF patients with cardiac tumors.

Indian pacing and electrophysiology journal·2026

Same author

Association Between Osimertinib Dose Reduction and Treatment Outcomes in First-Line EGFR-Mutated Advanced NSCLC: The Impact of Post-Progression Management.

Thoracic cancer·2026

Same author

A Case of Miliary Tuberculosis Complicated by Knee Joint Tuberculosis.

Case reports in infectious diseases·2026

Same author

Atrial Reverse Remodeling by Bachmann's Bundle Pacing With Improved Interatrial Dyssynchrony: Case Series.

Pacing and clinical electrophysiology : PACE·2026

Search research articles

Related Experiment Video

Updated: Sep 27, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Lung function decline in sarcoidosis.

Kiminobu Tanizawa¹, Tomohiro Handa², Sonoko Nagai³

¹Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Respiratory Investigation

|April 11, 2022

Summary

Lung function decline in sarcoidosis patients, defined by a 10% drop in forced vital capacity or 15% in diffusing capacity, is a significant predictor of mortality. This decline indicates a higher risk of death, independent of other lung health indicators.

Keywords:

Lung function Progressive fibrosing interstitial lung disease Pulmonary hypertension Sarcoidosis Survival

More Related Videos

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

Related Experiment Videos

Last Updated: Sep 27, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

Area of Science:

Pulmonology
Respiratory Medicine
Clinical Epidemiology

Background:

Progressive fibrosing interstitial lung disease is defined by declining lung function.
Sarcoidosis is a systemic inflammatory disease that can affect the lungs.

Purpose of the Study:

To evaluate the epidemiology of lung function decline in sarcoidosis.
To assess the clinical relevance and prognostic impact of lung function decline in sarcoidosis patients.

Main Methods:

Retrospective observational study at a general sarcoidosis clinic.
Lung function decline defined as a 24-month relative decline of ≥10% in %FVC or ≥15% in %DLco.
Analysis of lung function decline frequency and associations with subsequent lung function changes and survival.

Main Results:

14.0% of patients showed a ≥10% decline in %FVC and 16.6% showed a ≥15% decline in %DLco over 24 months.
Lung function decline was not associated with subsequent lung function decline.
A 24-month decline in lung function was significantly associated with worse survival, even after adjusting for CPI and PH.

Conclusions:

A 24-month decline in lung function is a risk factor for mortality in sarcoidosis.
This association persists irrespective of composite physiological index (CPI) and pulmonary hypertension (PH).
Monitoring lung function decline is crucial for risk stratification in sarcoidosis patients.